A simple LC‐MS/MS method to determine plasma and cerebrospinal fluid levels of albendazole metabolites (albendazole sulfoxide and albendazole sulfone) in patients with neurocysticercosis

González-Hernández, Iliana; Ruiz-Olmedo, María Isabel; Cárdenas, Graciela; Jung‐Cook, Helgi

doi:10.1002/bmc.1659

Cited by 19 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, as lumbar puncture is invasive, it would have been excessive to repeat it 10 days after the pretreatment lumbar puncture. This information would surely have been of interest, although previous studies have shown that there is a positive and significant correlation in albendazole sulfoxide concentration between the CSF and plasma . Our result shows the importance of using strategies to increase the concentration of albendazole sulfoxide in plasma.…”

Section: Discussionmentioning

confidence: 99%

Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis

Osorio

Carrillo‐Mezo

Romo

et al. 2018

The Journal of Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Extraparenchymal neurocysticercosis is the most severe form of cysticercosis, and response to treatment is suboptimal. We sought to determine how demographic and clinical characteristics and albendazole sulfoxide concentrations were related to cysticidal treatment response. We conducted a longitudinal study of 31 participants with extraparenchymal vesicular parasites who received the same treatment, albendazole 30 mg/kg/day for 10 days with dexamethasone 0.4 mg/kg/day for 13 days, followed by a prednisone taper. Response to treatment was determined by parasite volumes before and 6 months after treatment. Eight participants (25.8%) had a complete treatment response, 16 (51.6%) had a treatment response > 50% but < 100%, and 7 (22.6%) had a treatment response < 50%. Complete treatment response was significantly associated with higher concentrations of albendazole sulfoxide (P = .032), younger age (P = .032), fewer cysts (P = .049) and lower pretreatment parasite volume (P = .037). Higher number of previous cysticidal treatment courses was associated with a noncomplete treatment response (P = .023). Although the large proportion of participants with less than a complete response emphasizes the need to develop more efficacious pharmacologic regimens, the association of albendazole sulfoxide concentrations with treatment response highlights the importance of optimizing existing therapeutic regimens. In addition, the association of treatment response with parasite volume emphasizes the importance of early diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis

Osorio

Carrillo‐Mezo

Romo

et al. 2018

The Journal of Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this form, the drug passes through the blood-brain barrier and reaches the CNS where it exerts its therapeutic effect, so that the amount of ASOX in the cerebrospinal fluid is probably the main determinant of its efficacy in the treatment of NCC. Given the high correlation between ASOX levels in plasma and cerebrospinal fluid [26], monitoring ASOX plasma levels in patients during ABZ therapy may reflect the amount of the drug in the CNS.…”

Section: Discussionmentioning

confidence: 99%

Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis

Arroyo¹,

Bustos

Lescano³

et al. 2019

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background The efficacy of albendazole therapy in patients with parenchymal neurocysticercosis (NCC) is suboptimal. Plasma levels of albendazole sulfoxide (ASOX), the active metabolite of albendazole, are highly variable among patients. We hypothesized that high ASOX plasma levels during albendazole therapy may be associated with an increased antiparasitic efficacy. Methods ASOX plasma levels were measured at treatment day 7 in 118 patients with parenchymal NCC enrolled in a treatment trial. The relationships between increasing ASOX plasma levels with the proportion of cysts resolved and the proportion of patients with complete cyst resolution (evaluated by 6-month brain magnetic resonance) were assessed. Results There was a trend toward a higher proportion of cysts resolved and a higher proportion of patients cured with increasing quartiles of ASOX plasma levels. In patients with 3 or more brain cysts, the regression analysis adjusted by the concomitant administration of praziquantel (PZQ) showed a 2-fold increase in the proportion of cysts resolved (risk ratio [RR], 1.98; 95% confidence interval [CI], 1.01–3.89; P = .048) and 2.5-fold increase in the proportion of patients cured (RR, 2.45; 95% CI, .94–6.36; P = .067) when ASOX levels in the highest vs the lowest quartile were compared. No association was found in patients with 1–2 brain cysts. Conclusions We suggest an association between high ASOX plasma levels and increased antiparasitic efficacy in patients with parenchymal NCC. Nonetheless, this association is also influenced by other factors including parasite burden and concomitant administration of PZQ. These findings may serve to individualize and/or adjust therapy schemes to avoid treatment failure.

show abstract

“…Many analytical methods have been reported for the analysis of ABZ in pharmaceuticals using spectrophotometry (Lahane & Deokate, ), high‐performance liquid chromatography (HPLC) (De, Bera, & Pal, ) and ultra‐high‐performance liquid chromatography (UHPLC; Swamy, Basavaiah, Penmatsa, Vinay, & Prashanth, ). Similarly, several methods are described for the determination of ABZSO and/or other inactive metabolites of ABZ in human serum (Mirfazaelian, Dadashzadeh, & Rouini, ), bovine plasma (Belaz, Cass, & Oliveira, ), human cancer cell lines (Belaz et al, ), dog plasma (Khalil, El‐karbane, Azougagh, El‐harti, & Taoufik, ), human plasma (González‐Hernández, Ruiz‐Olmedo, Cárdenas, & Jung‐Cook, ; Saraner et al, ) and cerebrospinal fluid (González‐Hernández et al, ). Simultaneous analysis of ABZ and ABZSO is also reported in different biological matrices using HPLC (Kitzman, Cheng, & Fleckenstein, ), LC–MS/MS (Rathod et al, ; Wojnicz et al, ) and UPLC–MS/MS (Shen et al, ; Zhang et al, ).…”

Section: Introductionmentioning

confidence: 99%

Simultaneous densitometric determination of anthelmintic drug albendazole and its metabolite albendazole sulfoxide by HPTLC in human plasma and pharmaceutical formulations

Pandya

Sanyal

Shrivastav

2017

Biomedical Chromatography

View full text Add to dashboard Cite

A new, simple, accurate and precise high-performance thin-layer chromatographic method has been developed and validated for simultaneous determination of an anthelmintic drug, albendazole, and its active metabolite albendazole, sulfoxide. Planar chromatographic separation was performed on aluminum-backed layer of silica gel 60G F using a mixture of toluene-acetonitrile-glacial acetic acid (7.0:2.9:0.1, v/v/v) as the mobile phase. For quantitation, the separated spots were scanned densitometrically at 225 nm. The retention factors (R ) obtained under the established conditions were 0.76 ± 0.01 and 0.50 ± 0.01 and the regression plots were linear (r ≥ 0.9997) in the concentration ranges 50-350 and 100-700 ng/band for albendazole and albendazole sulfoxide, respectively. The method was validated for linearity, specificity, accuracy (recovery) and precision, repeatability, stability and robustness. The limit of detection and limit of quantitation found were 9.84 and 29.81 ng/band for albendazole and 21.60 and 65.45 ng/band for albendazole sulfoxide, respectively. For plasma samples, solid-phase extraction of analytes yielded mean extraction recoveries of 87.59 and 87.13% for albendazole and albendazole sulfoxide, respectively. The method was successfully applied for the analysis of albendazole in pharmaceutical formulations with accuracy ≥99.32%.

show abstract

A simple LC‐MS/MS method to determine plasma and cerebrospinal fluid levels of albendazole metabolites (albendazole sulfoxide and albendazole sulfone) in patients with neurocysticercosis

Cited by 19 publications

References 17 publications

Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis

Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis

Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis

Simultaneous densitometric determination of anthelmintic drug albendazole and its metabolite albendazole sulfoxide by HPTLC in human plasma and pharmaceutical formulations

Contact Info

Product

Resources

About